期刊
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION
卷 94, 期 6, 页码 F402-F406出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/adc.2008.150250
关键词
-
类别
资金
- Foundation for Paediatric Research
- Alma and K.A. Snellman Foundation (Oulu, Finland)
- Arvo and Lea Ylppo Foundation
- Sigrid Juselius Foundation (Finland)
Background: Weekly repeated antenatal corticosteroid treatment improves respiratory outcome but decreases fetal growth and may impair neurodevelopmental outcome. We have previously reported that a single repeat betamethasone (BM) dose neither decreased fetal growth nor improved the outcome of preterm infants during the first hospitalisation. Objective: To study prospectively whether a single repeat dose of BM influences neurodevelopment and growth within 2 years. Design: Women with imminent delivery before 34.0 gestational weeks were eligible if they remained undelivered for >7 days after a single course of antenatal BM. After stratification, a single repeat dose of BM (12 mg) or placebo was given. The children underwent neurological and psychometric examinations and a speech evaluation at a corrected age of 2 years. Setting: Prospective, blinded evaluation following the randomised multicentre trial. Patients: 259 (82%) surviving infants completed the 2-year follow-up, 120 in the BM group and 139 in the placebo group. Results: The rate of survival without severe neurodevelopmental impairment was similar in both groups (BM 98%, placebo 99%). The risk of cerebral palsy (BM 2%, placebo 1%), growth or re-hospitalisation rates (BM 60%, placebo 50%) did not differ between the groups. Conclusions: A single repeat dose of antenatal BM tended not to influence physical growth or neurodevelopment at 2 years of age.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据